ERBB2 and breast carcinoma: Since we have shown that trastuzumab increased HER480kDa and induced its nuclear translocation in HER2 positive breast cancer (Figure 2A and 2B), we tested whether a γ-secretase inhibitor (GSi) could prevent HER4 nuclear localisation induced by trastuzumab treatment.